Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1572476 | 0.75 | MAPT (0.52) | MAPTKDM4EALDH1A1HSD17B10TP53 | |
| SCHEMBL4772974 | 0.75 | RAB9A (0.39) | RAB9A | |
| SCHEMBL5387190 | 0.73 | KDM4E (0.53) | MAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL5377839 | 0.73 | KDM4E (0.31) | MAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL23088340 | 0.70 | ALDH1A1 (0.40) | MAPTKDM4EALDH1A1HSD17B10TP53 | |
| SCHEMBL280594 | 0.70 | PLG (0.39) | MEN1KMT2ARAB9ALIMK1 | |
| SCHEMBL31028460 | 0.70 | DYRK1A (0.38) | MAPTTP53LIMK1 | |
| SCHEMBL2466267 | 0.70 | JAK2 (0.39) | KDM4ERAB9A | |
| SCHEMBL23984468 | 0.70 | MAP2K4 (0.41) | MEN1KMT2AMAPTTP53IKBKB | |
| SCHEMBL29792703 | 0.70 | ALDH1A1 (0.40) | MAPTKDM4EALDH1A1HSD17B10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002030886-A2 | HETEROCYCLIC ANGIOGENESIS INHIBITORS | MATTHEWS BARRY R (AU) | 2002-04-18 | — | — | WO | claimed |
| US-20020128232-A1 | Heterocyclic angiogenesis inhibitors | STARPHARMA LIMITED (AU) | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128232-A1 | Heterocyclic angiogenesis inhibitors | KDR, CBR3, OGFR | MEN1 4847/4885KMT2A 3578/4885MAPT 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.